Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate

New England Journal of Medicine

Volumn 359, Issue 5, 2008, Pages 539-541

  Prins, Robert M ^a   Cloughesy, Timothy F ^a   Liau, Linda M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLIBLASTOMA VACCINE;

CASE REPORT; CD8+ T LYMPHOCYTE; CELL LYSATE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNITY; IMMUNOHISTOCHEMISTRY; LETTER; PRIORITY JOURNAL; VACCINATION;

EID: 48249102647     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc0804818     Document Type: Letter

References (5)

1. Deorah S, Lynch CF, Sibenaller ZA, Ryken TC. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus 2006;20:E1.
2. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25.
3. Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62:3347-50.
4. Ho KL, Gottlieb C, Zarbo RJ. Cytomegalovirus infection of cerebral astrocytoma in an AIDS patient. Clin Neuropathol 1991;10:127-33.
5. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008;10:10-8.